Fig. 8

Dual blockade of MET and EGFR inhibited NSCLC growth in vivo. Athymic nude mice bearing A549 CPNE1-overexpressing tumours were treated with gefitinib, JNJ-38877605 or both for 2 weeks. A, B The tumours were measured and weighed. Data represent the mean (± SD), and unpaired t test was used to verify the statistical significance at the last point. C Xenograft tumours were dissected and photographed. D Western blotting was used to analyse the protein levels of p-EGFR, p-MET, p-AKT and p-ERK in tumour tissues of different treatment groups. E A diagram showing that CPNE1 mediates NSCLC progression by interacting with RACK1 and activating MET signaling. *P < 0.05; **P < 0.01; ***P < 0.001